



14P36

00005.001275

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
YUZURU ABE, ET AL.  
Application No.: 10/550,030  
Filed: September 23, 2005  
For: THERAPEUTIC AND/OR  
PREVENTIVE AGENT FOR  
PULMONARY DISEASE )  
Examiner: Not Yet Assigned  
Group Art Unit:  
December 21, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.


Documents B, D, E, G-K and Q-U were cited in the International Preliminary Examination Report, already of record. (None was listed as being of category "X".) Additionally, documents I and L-P were cited at specification pages 1-2, 6 and 15. A concise explanation of their relevance may be found therein.

CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Lawrence S. Perry  
Attorney for Applicants  
Registration No.: 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3800  
Facsimile: (212) 218-2200

LSP\ac

ATTY DOCKET NO.  
**00005.001275**APPLICATION NO.  
**10/550,030**APPLICANT  
**YUZURU ABE, et al.**FILING DATE  
**September 23, 2005**GROUP  
**Not Yet Assigned**DEC 22 2005  
USPTO  
TRADEMARK  
SEARCHED  
RECORDED  
MAILED

## U.S. PATENT DOCUMENTS

*EXAMINER'S INITIAL	TRADEMARK DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
A	0 771 794	5/97	EP			
B	WO 03/066044	8/03	PCT			Abstract
C	1 424 326	6/04	EP			
D	WO 04/005276	1/04	PCT			Abstract
E	WO 02/098880	12/02	PCT			
F	WO 00/50402	8/00	PCT			
G	WO 00/51598	9/00	PCT			
H	WO 03/080049	10/03	PCT			
I	WO 96/36624	11/96	PCT			Abstract
J	WO 03/016279	2/03	PCT			Abstract
K	2002/537383	11/02	Japan			Abstract


## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

L	Pauwels, et al., "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease," <i>Am. J. Respir Crit Care Med.</i> , Vol. 163 (2001), pages 1256-1276
M	Schmidt, et al., "Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease," <i>Clinical and Experimental Allergy</i> , Vol. 29, Supp. 2 (1999), pages 99-109
N	Compton, et al., "Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study", <i>The Lancet</i> , Vol. 358 (2001), pages 265-270

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)ATTY DOCKET NO.  
**00005.001275**APPLICATION NO.  
**10/550,030**APPLICANT  
**YUZURU ABE, et al.**FILING DATE  
**September 23, 2005**GROUP  
**Not Yet Assigned**

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

O	Bernard, et al., "The American-European Consensus Conference on ARDS," <i>Am J Respir. Crit. Care Med.</i> , Vol. 149 (1994), pp. 816-824
P	Ware, et al., "The Acute Respiratory Distress Syndrome," <i>The New England Journal of Medicine</i> , Vol. 342, No. 18 (2000), pp. 1334-1349
Q	Teixeira, et al., "Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?" <i>TiPS</i> , Vol. 18 (1997), pp. 164-171
R	Ishibashi, et al., "Mansei Heisokusei Haishikkan no Chiryo Teopylline to Atarashii Phosphodiesterase IV Sogaiyaku," <i>Gendai Iryo</i> , Vol. 34, No. 9 (2002) , pages 2249-2254
S	Yamashita, Naomi, "Tiotropium to Phosphodiesterase IV Sogaiyaku," <i>Biomedicine &amp; Therapeutics</i> , Vol. 35, No. 11 (2001), pages 1255-1226
T	Nagasaki, Yukio, "Kokyuki Shikkan ni Taisuru Teophylline no Koka", <i>Kokyo to Junkan</i> , Vol. 44, No. 8, (1996), pages 839-845 (Abstract) AN 1996:553000
U	Häfner, et al., "Additive Effects of Phosphodiesterase-4 Inhibition on Effects of rSP-C Surfactant," <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 161 (2000), pages 1495-1500

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.